Skip to main content

Table 2 Clinical characteristics of study cohorts at the start of first-line therapy

From: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States

Characteristics Overall
N = 5807
RET+
N = 46
RET-
N = 5761
RET+ vs RET-
P value*
Body weight (kg)
 Mean (Sd) 75.7 (18.8) 74.9 (16.2) 75.7 (18.8) 0.81
 Median (IQR) 73.7 (62.1, 86.4) 70.1 (62.8, 86.4) 73.8 (62.1, 86.4)  
BMI category, n (%)
 Underweight 302 (5.4) 2 (4.7) 300 (5.4) 0.82
 Normal 2203 (39.1) 20 (46.5) 2183 (39.0)  
 Overweight 1843 (32.7) 13 (30.2) 1830 (32.7)  
 Obese 1289 (22.9) 8 (18.6) 1281 (22.9)  
 Missing/Unknown 170 3 167  
Stage at initial diagnosis, n (%)
 Stage I 486 (8.5) 3 (6.5) 483 (8.6) 0.34
 Stage II 335 (5.9) 0 (0.0) 335 (5.9)  
 Stage III 1154 (20.3) 9 (19.6) 1145 (20.3)  
 Stage IV 3714 (65.3) 34 (73.9) 3680 (65.2)  
 Missing/Unknown 118 0 118  
Histology, n (%)
 Non-squamous 4437 (79.6) 45 (100.0) 4392 (79.4) < 0.0001
 Squamous 1138 (20.4) 0 (0.0) 1138 (20.6)  
 Missing/Unknown 232 1 231  
Smoking status, n (%)
 Smoking history 4720 (81.5) 17 (37.0) 4703 (81.9) < 0.0001
 No smoking history 1071 (18.5) 29 (63.0) 1042 (18.1)  
 Missing/Unknown 16 0 16  
ECOG performance status, n (%)
 0 1438 (33.8) 19 (61.3) 1419 (33.6) 0.02
 1 2088 (49.1) 9 (29.0) 2079 (49.2)  
 2 595 (14.0) 2 (6.5) 593 (14.0)  
 3+ 136 (3.2) 1 (3.2) 135 (3.2)  
 Missing/Unknown 1550 15 1535  
RET fusion partner
 KIF5B 29 (63.0)
 CCDC6 11 (23.9)  
 NCOA4 3 (6.5)  
 Otherd 3 (6.5)  
EGFR positive, n (%)
 Yes 447 (18.8) 3 (8.6) 444 (18.9) 0.19
 No 1936 (81.2) 32 (91.4) 1904 (81.1)  
 Missing/Unknown 3424 11 3413  
ALK positive, n (%)
 Yes 80 (3.7) 0 (0.0) 80 (3.8) 0.64
 No 2086 (96.3) 34 (100.0) 2052 (96.3)  
 Missing/Unknown 3641 12 3629  
KRAS positive, n (%)
 Yes 233 (24.6) 0 (0.0) 233 (25.0) 0.05
 No 714 (75.4) 13 (100.0) 701 (75.1)  
 Missing/Unknown 4860 33 4827  
ROS1 positive, n (%)
 Yes 16 (1.2) 0 (0.00) 16 (1.2) 1.0
 No 1310 (98.8) 19 (100.0) 1291 (98.8)  
 Missing/Unknown 4481 27 4454  
BRAF positive, n (%)
 Yes 42 (4.9) 0 (0.0) 42 (4.9) 1.0
 No 820 (95.1) 7 (100.0) 813 (95.1)  
 Missing/Unknown 4945 39 4906  
MSI status, n (%)
 MSI high 7 (0.2) 0 (0.0) 7 (0.3) 1.0
 MSI stable 2849 (99.3) 22 (100.0) 2827 (99.3)  
 MSI intermediate 13 (0.5) 0 (0.0) 13 (0.5)  
 Missing/Unknown 2938 24 2914  
PD-L1 expressiona, n (%)
 Positive (≥ 1%) 1206 (47.4) 15 (68.2) 1191 (47.2) 0.06
 Negative 1337 (52.6) 7 (31.8) 1330 (52.8)  
 Missing/Unknown 3264 24 3240  
FMI PD-L1 expressionb, n (%)
 High Positive (≥50%) 390 (31.2) 2 (28.6) 388 (31.2) 0.21
 Low Positive (1–49%) 353 (28.2) 4 (57.1) 349 (28.1)  
 Negative 507 (40.6) 1 (14.3) 506 (40.7)  
 Missing/Unknown 4557 39 4518  
Time from metastatic diagnosis to FMI testc, days
 Mean (Sd) 86.7 (427.1) 135.9 (480.4) 86.3 (426.6) 0.43
 Median (IQR) 0 (0.0, 49.0) 1.5 (0.0, 441.0) 0 (0.0, 49.0)  
Adrenal metastases, n (%)
 Yes 657 (11.3) 3 (6.5) 654 (11.4) 0.48
 Not reported 5150 (88.7) 43 (93.5) 5107 (88.7) .
Bone metastases, n (%)
 Yes 2018 (34.8) 21 (45.7) 1997 (34.7) 0.12
 Not reported 3789 (65.3) 25 (54.4) 3764 (65.3)  
Brain metastases, n (%)
 Yes 1156 (19.9) 9 (19.6) 1147 (19.9) 1.0
 Not reported 4651 (80.1) 37 (80.4) 4614 (80.1)  
Distant lymph node metastases, n (%)
 Yes 808 (13.9) 7 (15.2) 801 (13.9) 0.83
 Not reported 4999 (86.1) 39 (84.8) 4960 (86.1)  
Liver metastases, n (%)
 Yes 697 (12.0) 13 (28.3) 684 (11.9) 0.0007
 Not reported 5110 (88.0) 33 (71.7) 5077 (88.1)  
Other metastases, n (%)
 Yes 4176 (71.9) 27 (58.7) 4149 (72.0) 0.05
 Not reported 1631 (28.1) 19 (41.3) 1612 (28.0)  
  1. *Missing values are not included in the statistical comparison between cohorts; comparisons based on t-test for continuous variables and Chi square test for categorical variables; Fisher’s exact test was used for cells with frequencies < 5
  2. aAs reported in the EHR or FMI test results available at the time of initiation of therapy
  3. bLimited to FMI test results available at the time of initiation of therapy
  4. cNegative days (ie, tests prior to advanced diagnosis) set to zero
  5. dOther fusions included TRIM24, GAS2 and FRD4A
  6. RET rearranged during transfection; Sd standard deviation; IQR interquartile range; BMI body mass index; ECOG Eastern Cooperative Oncology Group; FMI Foundation Medicine, Inc.; EHR electronic health record; EGFR epidermal growth factor receptor; PD-L1 programmed death ligand 1; MSI microsatellite instability; ALK anaplastic lymphoma kinase; KRAS Kirsten rat sarcoma viral oncogene homolog; ROS1 ROS proto-oncogene 1; BRAF v-raf murine sarcoma viral oncogene homolog B
\